Outcome of the randomized control screening trials on oral, cervix and breast cancer from India and way forward in COVID-19 pandemic situation.

Abstract

Indian researchers have conducted the randomized control screening trials on oral, cervix and breast cancers in different locations of India.1-5 These screening procedures were both simple and inexpensive. The outcomes of the trials were published in the high impact journals. Implementation and execution of these randomized control screening trials in Indian setup was a challenging task. According to the oral cancer screening trials, performing three rounds of visual inspection of the oral cavity will prevent at least 37 000 deaths worldwide.1 Visual examination of the cervix following the application of 3% to 5% acetic (VIA) acid in one-time screening for cervix cancer revealed a 35% reduction in morality (0.65 95% confidence interval [CI] [0.47-0.89]) when compared to the control arm.2 After four rounds of screening in the Mumbai VIA trial, it was reported that using the VIA screening test as a screening tool may avoid 22 000 cervical cancer deaths and 72 600 deaths in countries with poor resources each year.4 When a single round of cervical cancer screening using human papilomavirus (HPV) testing was conducted in the Osamanabad district, the results revealed a substantial reduction in the rate of advanced cervical cancers and related fatalities when compared to the control group.3 Furthermore, according to the Mumbai breast cancer screening trials, clinical breast examination by trained primary health care workers in four rounds resulted in nearly 30% reduction in mortality (0.71 95% CI [0.54-0.94]) among women aged ≥50 years.5 There were 80 654 women involved in the VIA study from Tamil Nadu,2 151 538 women in the Mumbai study for cervical and breast screening,4, 5 131 746 women in the cervical cancer screening by HPV testing, cytologic testing and VIA3 and 191 873 people in the oral cancer screening trial. 1 This sample size includes both intervention and control arms. All together more than half million people were involved in these trials. Table 1 summarizes the details of these trials. There is strong evidence from these randomized control screening trials that we can prevent the deaths from oral, cervix and breast cancer by implementing simple screening tests.1-5 The Population-Based Cancer Registry (PBCR) of the respected locations of the screening trials has played an important role in providing incidence and mortality data to the randomized control screening trials. 1-5 There are several challenges in implementing screening/early detection programs for these cancers in COVID-19 pandemic. The program managers of the screening programs must adjust their practises to simultaneously safeguard the people from COVID-19 and also prevent these cancers. To combat this, we may need to employ alternative methods such as self-sampling for HPV,6, 7 self-breast examination and self-oral inspection. The program administrators should use print, social media and television campaigns, to raise awareness of self-sampling of HPV, self-breast examination and oral examination. The collection of self-samples can be done with the assistance of a health workers. In Indian setup, health workers plays an important role in cancer prevention activities.8 The community must be trained to send images of suspected breast and oral premalignant lesions to the program manager using the mobile phone, who can further facilitate the diagnosis and treatment for the people who have tested screen positive. The government of India has started the screening program for cervix, breast and oral cancers in different parts of India.9 The current system should ensure that screen positive cases are diagnosed and treated. Not only is the screening test a crucial part of the randomized trial, but it also provides easy access to diagnosis and treatment for screen positive cases. All randomized control trials have demonstrated a decline in mortality as a result of a good referral system for diagnosis and effective treatment. The expertise gained by the Indian researchers must be used for capacity building and developing infrastructure in low-resource settings for early detection of breast, cervix and oral cancer. Countries with a high burden of oral, breast and cervix cancers, along with a population-based cancer registry, a good referral system of diagnosis and treatment, trained human resources and financial sustainability, can implement the screening programs. According to the reports, low- and middle-income countries have lot of limitations in implementing screening programs, so they should focus and prioritize early detection programs. The early detection program mainly focuses on raising awareness about cancer symptoms and making diagnosis and treatment more accessible for symptomatic cases.10 Policymakers must be made aware of the importance of utilizing these evidence of the randomized controlled trials to control oral, breast and cervical cancers, as well as the need to organise preventative activities in light of the COVID-19 pandemic. The authors declare no conflicts of interest.